Rua Bioscience (RUA) H2 2024 earnings summary

Executive summary

• Achieved first revenues in Australia and expanded distribution channels in key global markets, including Germany and the UK.

• Focused on a capital-light, export-led strategy centered on genetics and distribution, outsourcing cultivation and manufacturing.

• Reported a significant loss before tax, primarily due to one-off impairments, but positioned for sustainable revenue growth in FY25.

• Expanded social impact and sustainability initiatives, including the Compassionate Access Programme and GHG emissions reporting.

Financial highlights

• Revenue from customers was $86k, with total revenue and other income at $322k, down from $6.53m in FY23 (which included a $5.85m non-cash fair value gain).

• Loss before tax was $13.7m (FY23: $6.0m), mainly due to $9.2m in one-off impairments to goodwill, supplier contracts, and other assets.

• Cash and investments at year-end totaled $895k, with net assets of $6.8m.

• Net operating cash outflow was $3.7m for the year.

• Net tangible assets per share declined to $0.03 (FY23: $0.06).

Outlook and guidance

• Entering a new revenue growth phase, aiming for sustainable revenue and product launches in the UK by end of 2024.

• Plans to introduce legacy genetics into new markets, including Germany and Australia.

• Focused on scaling sales efforts internationally, supported by recent capital raise and pending facility sale.